Complete Response to Pembrolizumab in a Case of Microsatellite Instability-High, Castration-Resistant Prostate Cancer With Somatic MSH2 Mutation.
Gunji Kanako K, Hoshi Seiji S, Maruya Masahiro M, Hagino Risa R et al.
Microsatellite instability-high status has been associated with response to immune checkpoint inhibitors. However, clinical data on microsatellite instability-high castration-resistant prostate cancer and temporal changes in mismatch repair status remain limited. A 77-year-old man with castration-resistant prostate cancer underwent comprehensive genomic profiling, which showed microsatellite instability-high and tumor mutational burden-high status with a somatic MSH2 (c.366+1G>C) variant. Pembrolizumab decreased prostate-specific antigen levels and achieved a radiological complete response. Serial immunohistochemistry demonstrated preserved MSH2 expression at diagnosis and loss after docetaxel treatment, establishing a temporal change in MMR protein expression during the clinical course. Serial biopsies demonstrated a temporal loss of MSH2 expression, suggesting that MMR function and MSI status may have changed during treatment. However, acquisition of MSI-H could not be established because baseline molecular MSI status was unavailable. This case highlights the potential value of re-biopsy and reassessment of current tumor biology.